Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ROCHE FARMACEUTICA QUIMICA LDA

NIF 500233810
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €22,898,653 116 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €22,898,653 116 contracts
A2 · Late Publication €23,078,598,063 6,331 contracts
Contract published to BASE more than 10 days after the signing date
LOW €23,078,598,063 6,331 contracts
A5 · Threshold Splitting €26,112,774 266 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €26,112,774 266 contracts
A6 · Low Competition €130,757,094 93 contracts
Only one bidder participated in a competitive procedure
MEDIUM €130,757,094 93 contracts
A9 · Price Overrun €55,233 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €55,233 1 contracts
A9 · Abnormal Price Reduction €26,319,014,877 1,873 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €26,319,014,877 1,873 contracts
C3 · Missing Mandatory Fields €35,643,635 96 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €35,643,635 96 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

899
€3,868,347,887
159
€1,587,118,832
259
€879,737,792
150
€866,312,888
618
€846,372,143
306
€841,593,275
70
€834,639,457
1,000
€791,977,813
24
€770,392,816
103
€765,674,331
38
€747,275,352
81
€742,372,527
367
€698,589,811
524
€669,957,258
73
€661,866,242
45
€651,950,632
50
€623,265,140
37
€605,733,844
338
€604,344,776
444
€600,743,498
Page 1 of 4 · 69 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 2 · 93 contracts

IMUNOMODULADORES - PERTUZUMAB + TRASTUZUMAB - 1ºSEMESTRE
PT · 11299083 · Ao abrigo de acordo-qu...
A6 · Low Competition
€432,890 2025-03-20
IMUNOMODULADORES - MICOFENOLATO DE MOFETIL
PT · 11288546 · Ao abrigo de acordo-qu...
A6 · Low Competition
€20,396 2025-03-17
Ajuste direto para aquisição de G683 - Glofitamab [10 mg/10 ml; sol inj; frs] e G684-Glofitamab [2.5 mg/2.5 ml; sol inj; frs]
PT · 11306267 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€1,313,651 2025-03-14
2025001943 – Aquisição de medicamentos
PT · 11274991 · Ajuste Direto Regime G...
A6 · Low Competition
€14,038 2025-03-11
Fornecimento de Epoetina Beta ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 11252776 · Ajuste Direto Regime G...
A6 · Low Competition
€76,701 2025-02-27
Ajuste direto para aquisição de G683 - Glofitamab [10 mg/10 ml; sol inj; frs] e G684-Glofitamab [2.5 mg/2.5 ml; sol inj; frs]
PT · 11262472 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€1,313,651 2025-02-27
2025001513 – Aquisição de medicamentos
PT · 11250944 · Ajuste Direto Regime G...
A6 · Low Competition
€16,867 2025-02-26
IMUNOMODULADORES - BEVACIZUMA, OBINUTUZUMAB, POLATUZUMAB VEDOTINA E TO
PT · 11241363 · Ao abrigo de acordo-qu...
A6 · Low Competition
€440,559 2025-02-21
ANTIANEMICOS - METOXIPOLIETILENOGLICOL - EPOETINA BETA
PT · 11240383 · Ao abrigo de acordo-qu...
A6 · Low Competition
€369,259 2025-02-20
MEDICAMENTO EXCLUSIVO - ROCHE FARMACÊUTICA
PT · 11289122 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€110,315,520 2025-02-17
2025000125 – Aquisição de medicamentos
PT · 11192746 · Ajuste Direto Regime G...
A6 · Low Competition
€12,650 2025-01-28
1193/2024 - Ajuste direto para aquisição de G683 - Glofitamab [10 mg/10 ml; sol inj; frs] e G684-Glofitamab [2.5 mg/2.5 ml; sol inj; frs]
PT · 11191497 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€266,459 2025-01-28
Aquisição Medicamentos Exclusivos Roche – Ano 2025
PT · 11247810 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€440,684 2025-01-24
Aquisição do medicamento - Tocilizumab
PT · 11254568 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€75,519 2024-12-30
C/ BASE NO CPA 2023_491
PT · 11181924 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€299,993 2024-12-27
OBINUTUZUMAB 25 MG/ML SOL INJ FR 40 ML IV (2023/491)
PT · 11111552 · Ao abrigo de acordo-qu...
A6 · Low Competition
€18,694 2024-12-26
1193/2024 - Ajuste direto para aquisição de G683 - Glofitamab [10 mg/10 ml; sol inj; frs] e G684-Glofitamab [2.5 mg/2.5 ml; sol inj; frs]
PT · 11289045 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€18,644 2024-12-24
2024010839 – Aquisição de medicamentos
PT · 11102507 · Ajuste Direto Regime G...
A5 · Threshold Splitting A6 · Low Competition
€19,207 2024-12-20
ANTIANEMICOS - METOXIPOLIETILENOGLICOL
PT · 11097070 · Ao abrigo de acordo-qu...
A6 · Low Competition
€18,046 2024-12-19
1193/2024 - Ajuste direto para aquisição de G683 - Glofitamab [10 mg/10 ml; sol inj; frs] e G684-Glofitamab [2.5 mg/2.5 ml; sol inj; frs]
PT · 11441628 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields +1
€34,958 2024-12-17
2024010445 – Aquisição de medicamentos
PT · 11064628 · Ajuste Direto Regime G...
A6 · Low Competition
€11,230 2024-12-04
BEAD20240467 - AQUISIÇÃO DE IMUNOMODULADORES - ATEZOLIZUMAB
PT · 11007165 · Ao abrigo de acordo-qu...
A6 · Low Competition
€100,053 2024-11-04
ANTIANEMICOS - METOXIPOLIETILENOGLICOL
PT · 11007203 · Ao abrigo de acordo-qu...
A6 · Low Competition
€11,349 2024-11-04
BEAD20240473 - AQUISIÇÃO DE METOXIPOLIETILENOGLICOL
PT · 11008460 · Ao abrigo de acordo-qu...
A6 · Low Competition
€9,458 2024-10-31
BEAD20240509 - AQUISIÇÃO DE ANTIANÉMICOS - METOXIPOLIETILENOGLICOL-EPOETINA BETA
PT · 11008473 · Ao abrigo de acordo-qu...
A6 · Low Competition
€22,698 2024-10-31
Aquisição do medicamento - polatuzumab
PT · 11110692 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€49,913 2024-10-29
Fornecimento de PERTUZUMAB+TRASTUZUMAB ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 11012379 · Ajuste Direto Regime G...
A9 · Abnormal Price Reduction A6 · Low Competition
€170,214 2024-10-29
Aquisição de Bevacizumab - 2024 - ULSLO, EPE.
PT · 11010557 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€1,421 2024-10-25
2024008093 – Aquisição de medicamentos
PT · 10998242 · Ajuste Direto Regime G...
A6 · Low Competition
€25,300 2024-10-23
241G001497 - ENTRECTINIB 200 MG CAPS - ANO 2024
PT · 10987613 · Ajuste Direto Regime G...
A6 · Low Competition
€45,964 2024-10-23
BEAD20240405 - AQUISIÇÃO DE IMUNOMODULAORES - TRASTUZUMAB EMTANSINA
PT · 10970271 · Ao abrigo de acordo-qu...
A6 · Low Competition
€123,316 2024-10-15
BEAD20240448 - AQUISIÇÃO DE IMUNOMODULADORES - TOCILIZUMAB
PT · 10968864 · Ao abrigo de acordo-qu...
A6 · Low Competition
€12,787 2024-10-14
Ajuste direto para aquisição de B770 - Bevacizumab [25 mg/ml; 100 mg/ 4 ml; conc p/a sol p/a perfusão; frs] doentes em tratamento e T1592 - Tocilizumab [162 mg/ 0.9 ml; caneta].
PT · 10961727 · Ajuste Direto Regime G...
A6 · Low Competition
€18,385 2024-10-09
Tocilizumab 20 mg/ml sol inj fr 10 ml IV e Tocilizumab 20 mg/ml sol inj fr 20 ml IV
PT · 10927634 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,180 2024-09-06
IMUNOMODULADORES - RITUXIMAB - 3 MESES
PT · 10898897 · Ao abrigo de acordo-qu...
A6 · Low Competition
€140,387 2024-09-03
IMUNOMODULADORES - PERTUZUMAB + TRASTUZUMAB (EXCLUSIVOS) 2024
PT · 10898854 · Ao abrigo de acordo-qu...
A6 · Low Competition
€60,277 2024-09-03
IMUNOMODULADORES
PT · 10873024 · Ao abrigo de acordo-qu...
A6 · Low Competition
€179,996 2024-08-16
2024006483 – Aquisição de medicamentos
PT · 10926334 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€12,650 2024-08-13
Fornecimento de Atezolizumab 840 mg
PT · 10863979 · Ao abrigo de acordo-qu...
A6 · Low Competition
€177,048 2024-08-06
INIBIDORES DE TIROSINACINASES - ALECTINIB - 3 MESES
PT · 10840802 · Ao abrigo de acordo-qu...
A6 · Low Competition
€101,203 2024-07-29
IMUNOMODULADORES - TOCILIZUMAB - 3 MESES
PT · 10837389 · Ao abrigo de acordo-qu...
A6 · Low Competition
€22,211 2024-07-25
RISDIPLAM 60 MG PÓ SOL ORA
PT · 10852093 · Ajuste Direto Regime G...
A6 · Low Competition
€0 2024-07-23
BEAD20240365 - AQUISIÇÃO DE IMUNOMODULADORES - OCRELIZUMAB - 3 MESES
PT · 10815979 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A6 · Low Competition
€149,996 2024-07-11
IMUNOMODULADORES - MICOFENOLATO DE MOFETIL - 3 MESES
PT · 10815768 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction A6 · Low Competition
€24,894 2024-07-11
Fornecimento de Vemurafenib 240mg
PT · 10820951 · Ao abrigo de acordo-qu...
A6 · Low Competition
€64,078 2024-07-09
EMICIZUMAB
PT · 10806238 · Ao abrigo de acordo-qu...
A6 · Low Competition
€135,649 2024-07-05
Fornecimento de substância ativa: Faricimab 6mg
PT · 10852581 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€17,445 2024-06-20
EPOETINA BETA 30000 U.I./0.6 ML SOL INJ SER 0.6 ML IV SC
PT · 10989947 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€73,632 2024-06-11
EX/2026/2024 – MOSUNETUZUMAB Várias dosagens
PT · 10774038 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€673,092 2024-06-07
IMUNOMODULADORES - TOCILIZUMAB
PT · 10744202 · Ao abrigo de acordo-qu...
A6 · Low Competition
€14,065 2024-05-31
Next →
Overview
Total Value Won
€26,981,433,453
Contracts Won
8,787
Score 290915 · CRITICAL RISK
NIF
500233810
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

No director data imported yet.

Director and fiscal identity data for Portuguese companies can be found in the Registo Comercial (publicacoes.mj.pt).

Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned